Where I see patients (4)
Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.
The Lancet. Oncology
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
Journal of the National Cancer Institute
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.
European journal of nuclear medicine and molecular imaging
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
The proportion of patients who achieve a greater than 50% decline from baseline prostate specific antigen (PSA) (PSA50) drawn prior to C1D1, at any point in the treatment course, will be descriptively reported along with 95% binom...
18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas
Sensitivity of 18F-fluorocholine PET for the detection of abnormal parathyroid adenomas confirmed by pathology as compared to sestamibi imaging. Location of parathyroid adenoma at imaging as read by three blinded readers, will be ...
Fluoroethyltyrosine in Detecting Tumors in Participants With Recurrent Intracranial Tumors
Radiologists will classify lesions as having recurrent disease or not having recurrent disease. True Positives (TP) are defined as an FET PET read positive for tumor and pathology/follow-up demonstrates tumor recurrence in at leas...
Imaging of Solid Tumors Using FAP-2286
The frequency and severity of treatment emergent adverse events following FAP-2286 injection will be descriptively reported as classified and graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI ...
Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286
Proportion of participants with Adverse Events, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 will be reported.
Mechanisms of Resistance to PSMA Radioligand Therapy
The unit density sphere model will be implemented using OLINDA, a second-generation personal computer software for internal dose assessment in nuclear medicine to measure mean dose across all metastatic lesions. This approach uses...